Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624443 | 0.83 | CCNC (0.41) | PDE10ACCNCCDK8HRH3MAP4K4 | |
| SCHEMBL19498195 | 0.80 | PDE10A (0.40) | PDE10ACCNCCDK8MAP4K4 | |
| SCHEMBL19504484 | 0.78 | PDE10A (0.37) | PDE10ACCNCCDK8HRH3MAP4K4 | |
| SCHEMBL19504487 | 0.75 | HRH3 (0.40) | HRH3 | |
| SCHEMBL19504663 | 0.72 | DRD2 (0.36) | PDE10AHRH3 | |
| SCHEMBL27251619 | 0.70 | EGFR (0.32) | — | |
| SCHEMBL20651750 | 0.68 | KCNH2 (0.32) | — | |
| SCHEMBL20651755 | 0.68 | DRD2 (0.33) | — | |
| SCHEMBL19505171 | 0.66 | TIPARP (0.47) | HRH3ACACB | |
| SCHEMBL20651756 | 0.65 | SLC6A9 (0.42) | PDE10AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | PDE10A 3114/4885CCNC 4074/4885CDK8 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.